Wegovy for Teens: What the AAP Guidelines and STEP-TEENS Trial Show
FDA-approved for ages 12+ since 2022. What STEP-TEENS showed, how the AAP guidelines shifted, and what a proper pediatric evaluation should include.
In December 2022, the FDA approved Wegovy for adolescents aged 12 and older with obesity — the first GLP-1 medication approved for pediatric use. The approval was based on the STEP-TEENS trial and followed updated 2023 American Academy of Pediatrics guidelines that recommend pharmacotherapy as an option for adolescents aged 12+ with obesity.
The decision to start a 12–17 year old on a long-acting metabolic medication is significant. It's also, for some families, the appropriate clinical choice. This guide covers what the evidence shows, what the AAP actually recommends, what the decision involves, and what questions parents and adolescents should be asking.
What STEP-TEENS Showed
The pivotal trial for pediatric approval was STEP-TEENS — a Phase 3, 68-week, randomized, double-blind, placebo-controlled study in 201 adolescents (ages 12–17) with obesity. Participants received either semaglutide 2.4 mg weekly (with titration) or placebo, both combined with lifestyle intervention.
Key results:
- Adolescents on semaglutide lost an average of 16.1% of body weight from baseline vs. a 0.6% gain in the placebo group
- 73% of semaglutide participants achieved ≥5% weight loss (threshold for clinically meaningful weight loss) vs. 18% of placebo
- Significant improvements in waist circumference, A1C, lipids, liver enzymes, and quality-of-life measures
- Safety profile similar to adult semaglutide studies, with GI side effects being the most common
Results were published in New England Journal of Medicine in 2022 and led to the FDA approval shortly after.
What the AAP Recommends
In January 2023, the American Academy of Pediatrics released updated clinical practice guidelines for the evaluation and treatment of childhood obesity — the first major AAP guideline on obesity in 15 years. The guidelines represented a significant shift in approach.
Key recommendations:
- Ages 6+: Comprehensive intensive health behavior and lifestyle treatment (IHBLT) recommended as first-line for overweight and obesity
- Ages 12+: Pharmacotherapy may be offered alongside IHBLT for adolescents with obesity (BMI ≥ 95th percentile) or overweight with comorbidities
- Ages 13+: Bariatric surgery evaluation may be considered for severe obesity
The AAP explicitly moved away from "watchful waiting" — the historical default of delaying treatment in hopes that children would "grow out of it." The evidence showed watchful waiting was not effective for most adolescents with established obesity and often allowed the metabolic complications to worsen.
Pediatric obesity is not a lifestyle issue that resolves with encouragement. It's a chronic disease with identifiable metabolic components and documented long-term health consequences. The 2023 guidelines framed it accordingly — with screening, tiered treatment, and the addition of evidence-based pharmacotherapy as an option for adolescents whose disease hasn't responded to lifestyle intervention alone.
Who Qualifies for Wegovy Under the Pediatric Indication
Per the FDA label, Wegovy is approved for adolescents aged 12 and older with:
- Initial BMI at or above the 95th percentile for age and sex (the clinical definition of pediatric obesity)
- Used alongside a reduced-calorie diet and increased physical activity
The label does not require adolescents to have additional comorbidities — pediatric obesity alone qualifies, similar to how adult Wegovy is indicated for obesity (BMI ≥ 30) alone without requiring comorbidities.
Pediatric BMI percentiles are calculated based on age and sex-specific growth charts, not the adult absolute BMI thresholds. A BMI of 30 in a 14-year-old may or may not be in the 95th percentile — it depends on that adolescent's age and sex.
Practical Considerations
Dosing
Titration is the same as for adults — starting at 0.25 mg weekly and increasing every 4 weeks to the maintenance dose of 2.4 mg. Most adolescents titrate over 16–20 weeks. Some remain on lower doses if the higher doses produce intolerable GI effects.
Side Effects
The side effect profile in STEP-TEENS was similar to adult studies — nausea, vomiting, diarrhea, abdominal pain. Most were mild to moderate and resolved within the first few months. Discontinuation due to side effects was higher than placebo but manageable.
Growth Considerations
Longitudinal growth and pubertal development were monitored in STEP-TEENS and follow-up extensions. No adverse effects on height progression or pubertal markers were identified in the trial duration. However, the trial was 68 weeks — longer-term data on growth patterns through adolescence and into adulthood is limited.
Bone Mineral Density
Rapid weight loss in adolescents has historically raised concerns about bone accrual during the years when peak bone mass is being established. Current data on GLP-1 medications and bone health in adolescents is limited but generally reassuring. Standard monitoring of calcium, vitamin D, and age-appropriate weight-bearing activity is recommended.
Eating disorders — anorexia nervosa, bulimia, binge eating disorder, ARFID — are significantly more common in adolescence than most providers and parents realize. Starting a weight-loss medication in an adolescent with an active or emerging eating disorder can worsen outcomes substantially. Pre-prescription evaluation should include an eating disorder screen with a qualified mental health professional if there's any concern. Warning signs include: preoccupation with weight or body shape beyond what would be expected, restrictive eating patterns, binge eating, purging, compulsive exercise, or body image distress.
The Conversation With Your Adolescent
Starting a medication like Wegovy with a 12–17 year old is different from starting it with an adult. Several factors unique to adolescence matter:
Adolescent Agency and Consent
The adolescent should understand what the medication is, what it does, and what the commitment involves. The decision should feel like theirs, not purely their parents'. Coercive pressure from parents to lose weight is not an appropriate framing and can produce significant psychological harm — even when the medical recommendation is clinically sound.
Body Image Considerations
Adolescence is already a developmentally vulnerable period for body image. Framing matters significantly. Effective framings tend to emphasize health, energy, and functional goals rather than appearance or thinness. Weight-focused framings tend to do poorly and can contribute to body image distress.
Social and School Context
Side effects, injection schedules, and the fact of being on a medication can be visible or audible in school, sports, and social settings. Plan for this — privacy around the medication, discrete storage, and preparation for peer questions are all worth thinking about before starting.
Long-Term Expectations
Obesity medicine increasingly treats obesity as a chronic disease requiring long-term management — similar to type 1 diabetes, asthma, or hypertension. Setting the expectation that this may be a medication taken for years, not months, is appropriate. Adolescents should understand that discontinuing the medication typically leads to weight regain, and that decision should be made thoughtfully rather than reactively.
What to Expect at the Clinical Visit
A thorough pediatric or adolescent obesity medicine evaluation before prescribing should include:
- Detailed weight history, family history, and medical history
- Puberty staging and growth trajectory assessment
- Labs: A1C, fasting glucose, lipid panel, liver enzymes, thyroid function, kidney function
- Sleep history (pediatric OSA screening)
- Mental health screening including eating disorder screening
- Blood pressure and physical exam
- Discussion of lifestyle intervention quality and engagement
- Social and family support assessment
Shortcuts in this evaluation — brief video visits with no labs, for example — are inappropriate for pediatric GLP-1 prescribing. If your clinician is not conducting a thorough evaluation, find another one.
Insurance Coverage for Pediatric GLP-1
Coverage for adolescent Wegovy is variable and often restrictive:
- Medicaid: Most states cover Wegovy for pediatric obesity, though prior authorization is common
- Commercial insurance: Variable — many plans cover, some explicitly exclude
- Self-pay: List price is the same as adult Wegovy (~$1,350/month); manufacturer savings programs apply
Prior authorization typically requires documentation of BMI percentile, failed lifestyle intervention, absence of exclusion criteria, and supervision by an appropriate specialist (pediatric obesity medicine, pediatric endocrinology, or adolescent medicine).
Need FDA-approved brand-name medication?
Sesame Care connects you with licensed U.S. physicians who prescribe brand-name Wegovy and Zepbound.
Questions for the Pediatric Evaluation
- Based on my child's BMI percentile, labs, and medical history, is Wegovy the right option right now?
- What lifestyle intervention do we pursue alongside, and how is its quality measured?
- What's the monitoring plan — how often do we see you, what labs run, how do we track progress?
- How will we handle puberty and growth monitoring during treatment?
- What's the plan if side effects are significant at titration?
- What's the long-term framing — months, years, how long do we expect treatment to continue?
- What does "success" look like — scale weight, percentile, labs, function, or some combination?
The Bottom Line
Wegovy for adolescents 12+ is FDA-approved, AAP-endorsed, and backed by substantial trial data showing ~16% average weight loss with safety comparable to adult treatment. For adolescents with established obesity who haven't responded to lifestyle intervention alone, it's a legitimate clinical option. The decision is different from adult prescribing in important ways — adolescent agency, body image context, growth considerations, and eating disorder screening all matter. A thorough evaluation by a qualified pediatric or adolescent obesity specialist is essential. Shortcuts are not acceptable in this population. Done properly, adolescent GLP-1 therapy can change the trajectory of a chronic disease at a developmental stage when intervention is most effective.